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activation of the so-called mixed lymphocyte reaction 
used to characterize the major histocompatibility locus 
 [2, 3] . DCs are now recognized as the most potent class of 
antigen-presenting cells that play central roles in the ini-
tiation and control of the adaptive immune response  [4, 
5] . These cells ultimately help regulate the immune deci-
sions that moderate the balance between tolerance and 
immunity  [6, 7] .
 DCs are highly migratory cells that move from tissue 
to lymph nodes via afferent lymphatics where they then 
encounter naïve T cells ( fig. 1 ). At steady state, they reside 
in the peripheral organs as immature cells with a high 
phagocytic activity. This allows them to constantly sam-
ple antigens from the extracellular space. Proteolytic en-
zymes within the cell digest the captured antigens into 
fragments (peptides), which are then presented at the DC 
cell surface via major histocompatibility complex (MHC) 
class I and class II proteins. In the absence of inflamma-
tion, DCs have high phagocytic activity, low T cell stimu-
latory capacity, and are involved in the regulation of im-
mune tolerance. Upon exposure to microbial products or 
inflammatory stimuli, DCs undergo functional matura-
tion and licensing to become potent activators of T cell 
immunity. The induction of high levels of costimulatory 
molecules and the secretion of T cell-activating cytokines 
(IL-12) are factors that define the T cell stimulatory ca-
pacity of DCs. 
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 Abstract 
 Dendritic cells (DCs) are bone marrow-derived professional 
antigen-presenting cells that act as master regulators of ac-
quired and innate immune responses. While descriptions of 
cells with dendritic morphology in rodent kidneys date back 
to the early 1970s, a network of DCs in the mouse kidney has 
only recently been described. DCs acquire distinct pheno-
typic and functional characteristics depending on the micro-
environment and the disease stages. Concomitantly, their 
communication with cells of the adaptive immunity might 
have tissue-protective or tissue-deleterious consequences. 
This review summarizes results from recent studies on the 
role of DCs in experimental renal inflammation. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction  
 Dendritic cells (DCs) were first identified in the mouse 
as a discrete cell type in lymphoid organs (spleen) that 
were characterized by a large stellate morphology  [1] . 
These cells were subsequently found to be responsible for 
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 The relevant processes underlying the tolerogenic 
state are incompletely understood, but are thought to in-
volve active ‘suppressive’ signaling by endogenous ago-
nists rather then just an absence of ‘activating signals’  [8] . 
This review focuses on experimental studies in rodents 
on the role of DCs in renal inflammation. A general re-
view on the biology of DCs in human renal inflammation 
is discussed by Noessner et al. [9] in this issue of  Nephron 
Experimental Nephrology . 
 Mouse DC Subsets 
 Since their initial description, many different subsets 
of DCs have been identified based on expression patterns 
of marker proteins ( table  1 ;  fig.  2 ). Many excellent in-
depth reviews have recently addressed the issue of DC 
diversity and highlight the current difficulty in precisely 
defining DC subsets, as well as their distinction from 
monocytes and tissue macrophages  [10–14] . The pheno-
typic and functional plasticity has emerged as a hallmark 
of the DC/macrophage lineage. It now appears that the 
macrophage/DC distinction may be more accurately seen 
as a continuum of different cell stages. The surface mark-
er CD11c and high expression of MHC class II still repre-
sent reliable markers for the identification of DCs in mice 
and allow their discrimination from macrophages (which 
express CD11b and are MHC class II low). By contrast, 
CD11c is inappropriate for DC identification in humans 
as it is broadly expressed by nearly all monocytes and 
macrophages. In mouse, CD11c is additionally found on 
alveolar macrophages  [15, 16] . 
 With the exception of follicular DCs (FDCs), DCs be-
long to the hematopoietic cell lineage. These cells are de-
fined by the absence of lineage markers, combined with 
the expression of MHC class II, as well as a variety of ad-
hesion molecules and costimulatory molecules depend-
ing on their maturation and activation status. There are 
several types of DCs which are characterized by different 
markers and functions ( table 1 ;  fig. 2 ). Based on precur-
sor-product relationships, there is general agreement how 
to distinguish Langerhans cells (LCs) from plasmacytoid 
Mature/licensed DC:
high surface MHC-II
low endocytosis
high expression of co-
stimulatory molecules
low CCR1, CCR5
high CCR7
Immature DC:
high intracellular MHC-II
high endocytosis
low expression of co-
stimulatory molecules
high CCR1, CCR5
low CCR7
Tissue
Immature DC
Lymph node
Antigen capture
Microbial products
Mature/licensed 
DC
CTL
CTL
Treg
Th
Antigen clearance
tissue homeostasis
tolerance 
T cell priming
T cell tolerance
T cells
Migration
Maturation
Licensing
 Fig. 1. Life cycle of a DC. DCs reside in peripheral tissues as immature DCs with high intracellular MHC class 
II and low costimulatory molecules. Due to their high endocytosis and phagocytosis, they continuously sample 
the extracellular environment. Engulfed proteins reach the lymph node via immature/non-licensed DCs show-
ing constitutive low migratory activity. Due to low levels of costimulatory molecules and other not yet precise-
ly defined mechanisms, these non-licensed DCs are thought to help regulate tolerance to peripheral tissue an-
tigens. The presence of ‘danger signals’, e.g. microbial products, induces DC maturation and licensing which 
enhances their migratory activity to the lymph node due to upregulation of lymph node directing chemokine 
receptor CCR7. Microbial products also cause upregulation of costimulatory molecules and surface MHC class 
II, contributing to DC licensing which enables DCs to prime T cells in the lymph node. Activated T effector 
cells (cytotoxic T lymphocytes, CTL, or helper T cells, Th) or Treg, induced in situations where DCs are not 
licensed by ‘danger signals’, will return to the tissue to clear antigen and help establish tissue homeostasis or 
tolerance to tissue antigens. 
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(pDCs) and myeloid DCs. Myeloid DCs can be further 
subdivided into conventional (monocyte-independent) 
DCs (cDCs) and monocyte-derived DCs. 
 LCs were first recognized as different from splenic 
DCs based on the presence of Birbeck granules, which are 
Langerin positive. LCs reside in the epidermis and other 
stratified squamous epithelia. They are thought to have 
self-renewal capacity and thus act as their own cellular 
precursor. 
 The pDCs were initially isolated from tonsil, and were 
referred to as natural type I interferon-producing cells 
based on their high cytokine production in response to 
mPDCA1+, CD11clow,
CD4+, CD8–, Gr1+,
CD45RAhigh, B220+
Lymphoid
precursor
HSC
Myeloid
precursor
cDCs
LC
Type2
Plasmacytoid DC
Type 1
Myeloid marker positive [CD11b+]Myeloid marker negative [CD11b–]
Monocyte-
derived DC
CD8–, CD4+,
CD205/DEC205– 
CD8+, CD4–,
CD11b–,
CD205/DEC205+,
XCR1+, Clec9A+  
CD207/Langerin+,
CD11c+, CD1a–,
CD205/DEC205+,
EpCAM+, CX3CR1+  
 Fig. 2. Mouse DC development and DC 
subsets. A rough overview of DC develop-
ment and subset specification. DCs derive 
from hematopoietic precursors (HSC) and 
develop along two branches: the lymphoid 
branch gives rise to the pDCs and the my-
eloid branch gives rise to the tissue LCs 
(CD207/Langerin+) as well as the blood-
resident monocytes and cDCs. During the 
recruitment to peripheral tissues, DCs 
further diversify and may express a variety 
of markers. The cDCs can be further
divided into the so-called type 1 cDCs 
(CD8–) and type 2 cDCs (CD8+). For cor-
responding functions, see  table 1 . 
Table 1.  DC subsets, phenotypic markers, and functional characteristics (mouse)
DC subset Phenotypic markers Proposed function
LC myeloid marker positive [CD11b+]
CD207/Langerin+, CD11c+, CD1a–, CD205+, EpCAM+, CX3CR1+
first immunologic barrier to the external 
environment
pDC myeloid marker negative [CD11b–]
mPDCA1+, CD11clow, CD4+, CD8–, Gr1+, CD45RAhigh,
B220+ (B cell marker)
high production of type I interferons 
(IFN/), antiviral response 
Myeloid DC CD11chigh, CD45RA–
cDC type 1 CD8–, CD4+, CD11b+, DEC205– (CX3CR1), (F4/80), (CD103) CD4 T cell priming
cDC type 2 CD8+, CD4–, CD11b–, CD205/DEC205+, XCR1+, Clec9A+ cross-presentation ] CD8 T cell response
TGF- ] tolerance
Monocyte-derived DC (CX3CR1), (F4/80), (CD103) inflammation, tissue repair, homeostasis 
T he list of markers represents a selection that best defines and distinguishes one DC subset from the other subsets. Markers in bold 
are characteristic for the indicated DC subset. All DCs are negative for lineage markers (CD3, CD19, CD20) and CD56. mPDCA1 stands 
for murine plasmacytoid DC antigen 1. It was identified as bone marrow stromal cell antigen 2 [22, 53]. Clec9A is a C-type lectin and a 
receptor for necrotic cells; CD205/DEC205 is involved in antigen uptake, trafficking and antigen processing. Markers listed in round 
brackets may be variably expressed on myeloid conventional and monocyte-derived DCs in nonlymphoid tissues.
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viruses  [17–20] . In mice, pDCs express the B cell marker 
B220. They are CD11c low CD11b– CD45RA high  [21] and 
express murine plasmacytoid DC antigen 1, also known 
as bone marrow stromal cell antigen 2  [22] . 
 Murine myeloid DCs are further subdivided by
expression of CD8  . The CD8  – CD11c+ CD11b+ 
CD45RA– cells represent the most frequent myeloid DC 
subset, and are mainly involved in the priming of CD4 T 
cells. While less prevalent, the CD8  + DC subset is the 
principal producer of IL-12, and thereby drives Th1 de-
velopment and promotes CD8 T cell responses  [12] . The 
most outstanding feature of the CD8  + DC subset is its 
high capacity to cross-present antigen which is necessary 
to exert two opposing functions. On the one hand, it al-
lows priming of CTL against viruses that do not directly 
infect DCs, while on the other hand it induces CD8 T cell 
tolerance against self-antigens that are only expressed
in certain tissues and not by the DCs themselves  [23] .
Reflecting these functions, CD8  + DCs also express
Clec9A, a receptor for necrotic cells, and they can pro-
duce TGF-  which can promote the generation of induc-
ible T regulatory cells  [24] . 
 FDCs are a specialized subset of DCs which are not 
derived from the hematopoietic lineage  [25] . These cells 
are found in the B cell zone of secondary lymphoid tissues 
and can retain antigen for longer periods of time. FDCs 
can restimulate both B cells and T cells, and appear to 
help maintain immune memory in tandem with B cells. 
They do not express common myeloid or lymphoid mark-
ers.
 DCs in Non-Lymphoid Peripheral Tissues 
 The biology of DCs in non-lymphoid peripheral tis-
sues is a developing field that is revealing an increase in 
the complexity of DC subsets – as phenotypic and func-
tional adaptations occur in response to local tissue-spe-
cific microenvironments. The best-defined subset is the 
LC found in the skin. Other peripheral organs that have 
been studied in some detail with regard to their DC biol-
ogy include the gut, the lung [reviewed in  26 ] and more 
recently the kidney  [27–29] . Monocytes infiltrate tissue 
and can become phenotypically and functionally polar-
ized by specific tissue microenvironments giving rise to 
various non-lymphoid tissue DC subpopulations  [30] . 
The chemokine receptor CX 3 CR1 and the integrin   E  7 
(CD103) reciprocally define phenotypically, and func-
tionally, distinct myeloid DC subsets. The CX3CR1+ cells 
migrate poorly, and are thought to participate in the local 
activation of effector or memory T cells that infiltrate the 
tissue. The CD103+ DCs represent a smaller percentage 
of the tissue DC population and have been proposed to 
be related to the lymphoid CD8  + DCs. They are migra-
tory and have the capacity to cross-present antigen, and 
thus may be responsible for generating CTL immunity 
and tolerance to tissue-associated pathogens and anti-
gens, respectively  [23, 24, 31] .
 DCs in Animal Models of Renal Inflammation 
 Tubulointerstitial cells that showed a dendritic mor-
phology, expressed MHC class II molecules, were first 
identified in the kidney almost 20 years ago  [32, 33] . The 
lack of reliable DC specific markers and general difficul-
ties in isolating these cells has delayed the further char-
acterization of renal DCs as a unique cell type. Kruger et 
al. [34] made important early contributions to the field of 
renal DC biology. In 2004, they described a subpopula-
tion of tubulointerstitial cells expressing the murine DC 
marker CD11c+ in healthy murine kidneys. Further anal-
ysis of the CD11c+ cells showed that they were a non-ho-
mogenous cell population as shown by coexpression pat-
terns for MHC class II, F4/80 and CD11b (macrophage 
markers)  [34] . The cells were found to express various co-
stimulatory molecules indicating different maturation 
and activation stages  [34] . Functional analysis of the renal 
CD11c+ cell population further classified these as DCs, as 
demonstrated by their ability to activate naive T cells  [34] . 
 The potential role of renal DCs in the onset and pro-
gression of kidney diseases has been subject of many 
studies in the mouse kidney, which have been recently 
reviewed in detail  [35–38] . While the current data illus-
trate various roles of DCs in the disease process, our un-
derstanding of DCs in renal diseases is still incomplete. 
Some studies have illustrated protective effects of renal 
DCs, other studies support a proinflammatory activity in 
renal disease settings. 
 DCs in Nephrotoxic Glomerulonephritis 
 In the most commonly used glomerular injury model 
(i.e. nephrotoxic nephritis, NTN), an accumulation of 
CD11c+ cells within the tubulointerstitial compartment, 
and accentuated in the periglomerular space around in-
flamed glomeruli was observed, while no positive cells 
were found within the inflamed glomerular tufts  [34] . 
CD11c+ cells isolated from nephritic kidneys demon-
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strated an increased potential for T cell activation as com-
pared to those from healthy mice  [34, 39] . To analyze the 
functional relevance of these infiltrating cells in NTN, 
Scholz et al.  [39] depleted CD11c+ cells in nephritic 
CD11c-DTR-mice after 4 and 10 days of NTN induction. 
This led to an aggravation of the disease. Unexpectedly, 
an increased severity of tubulointerstitial and glomerular 
damage, proteinuria and decreased creatinine clearance 
were described in animals depleted of DCs. In addition, 
they demonstrated that renal DCs from nephritic mice 
not only induced the production of the Th1 cytokine 
IFN-  , but also fostered an increase in secretion of the 
anti-inflammatory cytokine IL-10 by CD4+ Th1 cells 
 [39] – previously been shown to attenuate crescentic GN 
 [40] . These data suggest a renoprotective role of renal 
DCs in early NTN, probably through induction of IL-10. 
Recently, a functional switch of renal DCs in NTN – de-
pending on the disease stage – has been described  [41] . 
CD11c+ cells acquired a proinflammatory functionality 
during the course of the disease as shown by their in-
creased expression of costimulatory molecules such as 
CD80 or CD86, and secretion of proinflammatory cyto-
kines including TNF-  and interleukin-12. At the same 
time, the production of the suppressive molecule ICOS-L 
was found to be decreased. By contrast, the acquired pro-
inflammatory activity led to an increased activation of T 
cells in the later stages of NTN as defined by enhanced 
production of proinflammatory cytokines IFN-  , TNF-
  , IL-17, IL-2, and IL-6  [41] . In the nephritic mice, pro-
teinuria resulted in increased capture of antigen by inter-
stitial DCs as compared to healthy mice, indicating a
potential harmful role of proteinuria by stimulating ne-
phritogenic immune responses  [41] . In contrast to the ob-
servations at the early stage of NTN, the authors found 
an attenuation of the disease after depleting CD11c+ cells 
at a late stage of NTN, suggesting a switch of renal DCs 
from a protective to an aggravating functionality  [41] .
 DCs in T Cell-Mediated Glomerulonephritis 
 In a model of T cell-mediated glomerular injury, ad-
ditional roles of renal DCs were described by Heymann 
et al.  [42] . They generated transgenic mice selectively ex-
pressing foreign model autoantigens (ovalbumin, OVA, 
or hen egg lysozyme) in podocytes. This was followed by 
an adoptive transfer of T cells specifically recognizing the 
antigens (OT-I cells: OVA-specific CD8+ CTLs; OT-II 
cells: OVA-specific CD4+ Th cells). The authors showed 
that injection of a single T cell type did not result in renal 
damage, while coinjection of CD8+ CTLs and preacti-
vated CD4+ T cells into the transgenic mouse strain in-
duced periglomerular accumulation of T cells, DCs, and 
macrophages  [42] . Repeated injection of OT-I and OT-II 
cells for 4 weeks led to pronounced tubulointerstitial in-
filtration by mononuclear cells and the development of 
GN. In this experimental setting, renal DCs played an 
important role in the control of T cell infiltration and 
maintenance of the periglomerular infiltrate as depletion 
of CD11c+ cells resulted in rapid disappearance of infil-
trating cells and attenuation of the disease  [42] . Intersti-
tial renal DCs cross-presented glomerular autoantigen 
and activated CD8+ CTLs (in renal lymph nodes), which 
in turn were activated to proliferate and eventually infil-
trate the kidney leading to further OVA release. The pro-
inflammatory activity of renal DCs was amplified by pre-
sentation of the glomerular autoantigen to CD4+ T cells 
in the kidney, and resulted in cytokine and chemokine 
secretion, further amplifying mononuclear infiltration of 
the periglomerular space  [42] . Based on these results, kid-
ney DCs appear to serve as a potential link between glo-
merular injury and disease progression to the tubuloin-
terstitium. 
 DCs in Experimental Lupus Nephritis 
 Glomerulonephritis is one of the most common man-
ifestations of systemic lupus erythematosus that affects 
30–60% of the patients. It is initiated by glomerular de-
position of immune complexes followed by an imbalance 
of cytokine homeostasis resulting in renal inflammation. 
Several animal models mimicking human lupus have 
been established, such as MRL/lpr or NZB/W F1 mice 
which carry allelic variants or mutations in specific genes 
leading to dysregulation of the cellular and humoral im-
munity  [43–45] . Studies analyzing the contribution of 
resident renal DCs to the pathogenesis of lupus nephritis 
indicate a proinflammatory role of this cell subset  [45–
47] . Iwata et al. [46] have recently shown that treating 
MRL/lpr mice with a p38 MAPK inhibitor reduced the 
infiltration of immature and mature CD11c+ DCs into 
the kidney and spleen and attenuated renal pathological 
changes including proliferative glomerulonephritis and 
interstitial/perivascular damage. In addition, they ob-
served that p38 inhibition led to a decrease in production 
of the proinflammatory mediator high mobility group 
box (HMGB-1) protein in vivo and to inhibition of DC 
maturation and HMGB-1 excretion in vitro  [46] .
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 Castellano et al. [47] investigated the contribution of 
renal DCs and complement production in a murine 
model of progressive lupus nephritis. The authors found 
local and time-dependent synthesis of C1q, a compo-
nent of the classical complement pathway, in kidneys of 
MRL/lpr mice. Confocal microscopy analysis identified 
renal CD11c+ DCs as the source of the C1q  [47] . These 
results suggest that DCs participate in the ‘autoimmu-
nity’ of lupus nephritis via secretion of proinflamma-
tory proteins, activation of the complement system and 
thus promote renal inflammation and progression of 
the disease. 
 DCs in Ischemic Acute Kidney Injury 
 The various animal models discussed above ad-
dressed events in the glomerular compartment; the fol-
lowing part will focus more on models of interstitial in-
jury. In a model of acute renal ischemia/reperfusion in-
jury (IRI), Dong et al. [48] identified resident renal DCs 
as the major source of the inflammatory mediator TNF-
  . Flow cytometry analysis of bone marrow-derived 
(CD45+) cells indicated a proportional increase in all 
CD45+ cell populations (monocytes, neutrophils, T cells 
and F4/80– DCs) in ischemic kidneys, with the exception 
of F4/80+ DCs, which remained unchanged  [48] . The 
CD11c+ F4/80+ CD11b+ DCs were shown to be the pre-
dominant cell type among the TNF-expressing cells. 
Treatment with clodronate before onset of IRI, which de-
pletes macrophages and DCs, resulted in a marked re-
duction of TNF secretion by total and CD45+ renal cells, 
confirming resident renal DCs as major producers of 
TNF in early IRI  [48] . 
 A recent study by Lech et al. [49] proposed a protective 
role of renal DCs in postischemic acute renal failure. The 
authors demonstrated that the single Ig IL-1-related re-
ceptor (SIGGIR) suppresses immune cell activation in 
postischemic acute renal failure as SIGGIR-deficient 
mice displayed an aggravation of the disease  [49] . IRI in 
SIGGIR-deficient mice showed an enhancement of in-
terstitial leukocyte recruitment, transendothelial migra-
tion, and increased Il-6, CCl2, and CXCl2 mRNA ex-
pression in CD11b+ cells, but not in tubular epithelial 
cells. Depletion of DCs with clodronate prevented aggra-
vation of IRI in the SIGGIR-deficient mice suggesting a 
suppressive role of renal SIGGIR-expressing DCs in IRI 
 [49] . 
 Kim et al. [50] investigated the role of renal DCs in 
the recovery phase of IRI. The authors showed that in-
travenous clodronate treatment after IRI resulted in a 
preferential depletion of renal CD11c+ F4/80+ DCs on 
day 7. While previous studies had demonstrated that 
clodronate depletion before IRI resulted in a marked de-
crease in kidney damage, Kim et al. [50] observed that 
depletion of renal DCs after IRI led to an impaired kid-
ney recovery as it was associated with (a) increased 
apoptosis, (b) impairment of tubular cell proliferation, 
and (c) increased inflammatory milieu as shown by 
higher number of neutrophils in the kidney, and higher 
expression levels of proinflammatory cytokines and re-
duced levels of IL-10. Renal CD11c+ DCs isolated in the 
recovery phase of IRI (day 7) displayed a rather anti-
inflammatory expression profile (lower levels of proin-
flammatory TNF-  , IL-6 and IFN-  , with increased 
production of the anti-inflammatory IL-10), as com-
pared to renal DCs isolated at the early perfusion phase 
(day one). These results, as well as the fact that the adop-
tive transfer of DCs to clodronate-treated mice could 
partially reverse renal injury, indicate a beneficial role 
of renal DCs in the recovery phase of IRI by changing 
from a pro- to an anti-inflammatory phenotype and 
modulation of the immune response  [50] . 
 DCs in Cisplatin-Mediated Acute Kidney Injury 
 Cisplatin is a widely used anticancer drug, with ad-
verse side effects on acute renal function caused by tubu-
lar injury. Recent studies by Tadagavadi and Reeves  [51, 
52]  investigated the contribution of renal DCs in a model 
of cisplatin nephrotoxicity. They used CD11c-DTRtg 
mice in which DCs expressed the green fluorescent pro-
tein and the diphtheria toxin receptor  [51] . Ablation of 
CD11c+ DCs before cisplatin treatment resulted in an ag-
gravated renal injury as shown by an increased tubular 
injury, increased neutrophil infiltration and reduced sur-
vival rates  [51] . By using mixed bone marrow chimeras
in which 50% of the DCs were WT- and the other 50% 
CD11c-DTRtg-derived DCs, the authors could exclude 
inflammatory effects of dead or dying DCs in the DC-
ablated mice on the worsening of the nephrotoxicity. DT 
treatment of these chimeric mice had no effect on the se-
verity of renal dysfunction  [51] . Treatment of mice with 
cisplatin increased the production of ICOS-L by renal 
DCs, a known inducer of IL-10. These results suggest that 
renal DCs can attenuate toxin-induced acute kidney in-
jury by modulating the inflammatory response. In a sec-
ond study, the authors used the same model system to 
determine the role of endogenous and DC-released anti-
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inflammatory IL-10  [52] . Treating mice with cisplatin re-
sulted in activation of IL-10 receptor (IL-10R) signaling 
as shown by increased serum IL-10 levels, renal IL-10R1 
expression, and renal STAT3 phosphorylation. IL-10-de-
ficient mice displayed a worse outcome in cisplatin ne-
phropathy with decreased renal function, higher expres-
sion levels of inflammatory chemokines, and an in-
creased infiltration of IFN-  -producing neutrophils  [52] . 
To further characterize the source of IL-10, the authors 
used mixed bone-marrow chimeric mice where leuko-
cytes were derived from CD11c-DTRtg and IL-10 KO 
mice. Mixed bone marrow chimeric mice lacking IL-10 
production by DCs displayed a greater decrease in renal 
function than mice with IL-10-producing DCs. This is 
consistent with a protective effect of DCs mediated by 
DC-derived IL-10 in the context of cisplatin nephrotox-
icity  [52] .
 Conclusion 
 Taken together, these studies suggest various roles for 
renal DCs depending on the intrarenal inflammatory 
conditions and the maturation state of the resident DCs. 
However, why renal DCs appear to switch between ‘good 
cops’ and ‘bad cops’ in renal inflammatory disorders, and 
what the contribution of DC maturation is to the progres-
sion of renal disease, remains to be seen.
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